Kisspeptin vs PT-141 in Women: Study Populations and Measured Outcomes

PT-141 has treatment data for low desire in women. Kisspeptin has only a small brain-response experiment. You cannot rank them as two treatments because researchers measured different results in very different settings.

Who was in each study?

HSDD means ongoing low sexual desire that distresses you. The PT-141 trials enrolled 1,267 premenopausal women with HSDD, mean age 39. Women used bremelanotide 1.75 mg or placebo as an as-needed shot under the skin for 24 weeks RECONNECT Phase 3.

The kisspeptin trial randomized 40 premenopausal women with HSDD (32 completed both visits, mean age 29.2) at a UK research center. Each woman received a 75-minute drip into a vein with kisspeptin-54 on one visit and placebo on another visit kisspeptin trial in women.

What did researchers actually measure?

In the PT-141 trials, women reported desire on a short desire questionnaire and distress on a distress question about low desire. Women who used bremelanotide reported desire scores that rose 0.35 points more than with placebo, and distress scores that fell 0.33 points more than with placebo RECONNECT Phase 3.

In the kisspeptin trial, researchers measured blood-flow responses in the brain while women watched erotic videos and viewed faces of varying attractiveness. Blood-flow response shows where brain activity shifts during a task, and the trial did not test week-to-week desire as a clinical outcome. Kisspeptin also raised reproductive hormones during the infusion, with mean LH up 2.75 IU/L and mean FSH up 0.37 IU/L kisspeptin trial in women.

Why aren't these the same kind of evidence?

The PT-141 trials followed a large group for months and captured common side effects. In the combined main trials, 40.0% of women who used bremelanotide reported nausea compared with 1.3% with placebo, 20.3% reported flushing compared with 1.3%, and 11.3% reported headache compared with 1.9% bremelanotide safety review. The kisspeptin experiment gave a single short infusion to 32 women and reported no adverse effects kisspeptin trial in women.

No trial tested kisspeptin against PT-141 in the same women, so a change on a brain scan cannot be placed beside a change in desire and distress scores. If distressing low desire is your concern, you can review your history and assess the HOD treatment path by starting your plan.